Company
Scancell Holdings PLC
LON:SCLP
Scancell is a late-stage clinical biotechnology company developing targeted, off-the-shelf, active immunotherapies, generated by the ImmunoBody® and Moditope® platforms, designed to stimulate durable anti-tumor responses. The lead product, iSCIB1+, is a DNA ImmunoBody® that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma.
328 stories · page 1 of 4
Scancell inks licensing deal for technology that will aid development of new cancer treatment
It is teaming up with Vaccitech, which has developed a technology that will aid the manufacturing and formulation process
Scancell enrols first patient in cancer trial expansion
Recruitment has started using Modi-1 in combination with a checkpoint inhibitor
Scancell reports on year of 'strong operational and clinical progress'
Professor Lindy Durrant, chief executive officer of Scancell, said the company looks forward to "reporting further progress on the development of our products as we reach several key clinical milestones over the next financial year"
Scancell says executive chairman John Chiplin to step down
The company also announced that its co-founder and former CEO Richard Goodfellow intends to retire as a non-executive director
Scancell signs exclusive deal with cancer giant Genmab for anti-glycan antibody
The deal is worth up to US$208mln in upfront and milestone payments
Scancell to provide new insights on its monoclonal antibodies technology
The updates will be provided to delegates at the EuroMAbNet 12th Annual Meeting in Hamburg
Scancell enrols and doses first patient in cohort two of Modi-1 clinical trial
Approval of dose escalation a ‘significant safety milestone for the company’
Scancell targets emerging class of cancer treatment with latest addition to pipeline
It will use its GlyMab platform to develop T-cell bispecific antibodies or TCBs
Scancell Holdings expands phase II trial of cancer drug SCIB1
The new group of patients will receive what's called a therapeutic doublet of drugs alongside the company's treatment
Scancell treats first patient with Modi-1 cancer vaccine
The first patient was treated at Hammersmith Hospital, part of the Imperial College trust, and one of up to 20 UK clinical trial sites in the trial
Scancell recruiting patients for Modi-1 cancer trial
"The opening of recruitment for patients into our ModiFY clinical trial is a major step forward for the company," said Professor Lindy Durrant, the CEO of Scancell
Scancell says South African authorities have signed off a broadening of its Covid study
The real-world approach will allow researchers to garner meaningful data on safety and how well the drug works. It will also accelerate the recruitment process
Scancell's new platform has generated five new assets targeting cancer; inks deal with fourth partner for new platform
In the same announcement, investors were told the company has inked an agreement with an unnamed ‘major European pharmaceuticals company’